Infectious Diseases Treatment Industry Growth Overview: USA & Top Pharma Insights

infectious diseases treatment market size reached US$ 189.09 Billion in 2024 from US$ 182.65 Billion in 2023 and is expected to reach US$ 264.75 Billion by 2033, growing at a CAGR of 3.9% during the forecast period 2025-2033

According to DataM Intelligence has published its latest report on the "Infectious Diseases Treatment Market Size 2025," delivering comprehensive insights into key growth drivers, market segmentation, regional trends, and competitive revenue analysis. The report highlights the market size in both value and volume, CAGR projections, and emerging opportunities that help businesses identify growth potential and craft winning strategies. With a clear, data-driven outlook on current developments and future trends, this research is a must-read for companies seeking to stay ahead in Market.

The market is growing rapidly due to rising antimicrobial resistance (AMR), projected to cause 1.91 million deaths by 2050, driving investments in new antibiotics and stewardship programs. Pandemic-driven innovation in antivirals and vaccines like Pfizer's Paxlovid and AstraZeneca/Sanofi's Beyfortus alongside platform-based biologics, is boosting R&D, regulatory support, and procurement, fueling sustained market expansion.

The success of mRNA vaccines, including Moderna's mRNA-1273 and Pfizer-BioNTech's BNT162b2 for COVID-19, has highlighted the potential of platform-based viral therapeutics, paving the way for influenza, RSV, and other viral vaccines. Antivirals like Pfizer's Paxlovid and Merck's Lagevrio (molnupiravir) have offered effective outpatient treatment for high-risk COVID-19 patients, driving strong demand. Continued investment in next-generation antiviral platforms and the need for rapid responses to emerging viral outbreaks keep viral infections as the top market contributor.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/infectious-diseases-treatment-market?kb

Key Market Highlights:

North America leads the infectious disease treatment market with 43.2% revenue in 2024.

Asia-Pacific is the fastest-growing region at a 5.2% CAGR.

Viral infections dominate with 44.7% share.

Major players include Pfizer, AbbVie, Gilead, Merck, Sandoz, B. Braun, Bayer, AstraZeneca, and Novartis.

Top Key Companies:

Pfizer Inc., AbbVie, Gilead Sciences, Inc., Merck & Co., Inc., Sandoz Group AG, B. Braun SE, Bayer AG, AstraZeneca, and Novartis AG, among others.

Growth Projection:

The Global Infectious Diseases Treatment Market is set to witness significant growth between 2025 and 2032. While 2024 reflects steady progress, the increasing adoption of innovative strategies by leading players is expected to accelerate growth across the projected horizon. This creates a strong landscape of opportunities for businesses looking to expand, invest, and stay competitive in a rapidly evolving market.

Growth Drivers:

The growing antimicrobial resistance (AMR) crisis is fueling the infectious disease treatment market, with AMR projected to cause 1.9 million deaths annually by 2050. Pharma is responding with novel antibiotics like Pfizer's Zavicefta, Merck's Zerbaxa, and Shionogi's Fetroja, driving investment, innovation, and regulatory support.

Restraints:

Rapid pathogen mutations limit drug and vaccine effectiveness, shorten product lifecycles, and increase R&D costs. Variants like SARS-CoV-2 and resistant fungi such as Candida auris challenge market stability and profitability.

Market Intelligence Research Process:

The Infectious Diseases Treatment Market research report by DataM Intelligence leverages both primary and secondary data sources to deliver deep insights. It explores a wide range of factors shaping the industry from government regulations, market conditions, and competitive dynamics to historical trends, technological advancements, upcoming innovations, and potential challenges. This comprehensive analysis highlights growth prospects while addressing barriers, helping businesses navigate volatility and seize new opportunities

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=infectious-diseases-treatment-market

Key Market Segments:

Viral infections lead the infectious disease treatment market with a 44.71% share in 2024.

The bacterial infections segment is the fastest-growing in the infectious disease treatment market, holding a 31.79% share in 2024.

By Infection Type: (Viral Infections, Bacterial Infections, Fungal Infections, and Parasitic Infections)

By Drug Class: (Antibacterials, Antivirals, Antifungals, Antiparasitic Drugs, and Others)

By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Global Growth Regions:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Regional Trends

US & Europe Infectious Diseases Treatment Market Trends

In the US, high rates of chronic viral infections like HIV and hepatitis C drive demand for antiviral therapies, with FDA-approved drugs such as Gilead's Biktarvy, ViiV Healthcare's Juluca, and Merck-adjacent antivirals generating billions in revenue. The COVID-19 pandemic reinforced North America's leadership through rapid approvals of mRNA vaccines, including Pfizer-BioNTech's BNT162b2 and Moderna's mRNA-1273, and emergency-use antivirals like Pfizer's Paxlovid and Merck's Lagevrio.

For bacterial infections, the US sees high incidence of hospital-acquired multidrug-resistant infections, with therapies such as Pfizer's Zavicefta (ceftazidime-avibactam) and Merck's Zerbaxa (ceftolozane-tazobactam) addressing Gram-negative pathogens. Advanced biologics, monoclonal antibodies, and next-gen vaccines, including Sanofi/AstraZeneca's Beyfortus (nirsevimab) for RSV, further boost the market. Multidrug-resistant pathogens have also driven adoption of Shionogi's Fetroja (cefiderocol) and other hospital-targeted antibiotics.

In Europe, antimicrobial resistance (AMR) drives significant market activity, with 35,000 deaths annually reported by the ECDC due to resistant infections. Regulatory support from the EMA has accelerated approvals of high-value therapies, including Pfizer's Zavicefta, Shionogi's Fetroja, and Gilead's Biktarvy. Vaccine uptake is strong with EMA-approved products like Pfizer-BioNTech's BNT162b2, Moderna's mRNA-1273, and Sanofi Pasteur's Vaxigrip Tetra, alongside preventive biologics such as Beyfortus for RSV. Europe's aging population, high prevalence of chronic viral infections, and hospital-acquired resistant pathogens sustain demand for advanced therapies, supporting steady market growth.

This positions North America as the leader in revenue, while Europe focuses on advanced therapies and prevention, complementing Asia-Pacific's rapid adoption of novel treatments and vaccines.

Benefits of the Report:

Chapter 1: Introduces the report with an overview of coverage summarizing key market segments by region, product type, and application. It offers a clear snapshot of market size, segment-wise growth potential, and both short- and long-term industry outlook.

Chapter 2: Brings forward the most valuable market insights and reveals the game-changing emerging trends shaping the industry's future.

Chapter 3: Provides a detailed analysis of the competitive landscape among Infectious Diseases Treatment covering revenue shares, strategic initiatives, and the latest mergers & acquisitions.

Chapter 4: Delivers comprehensive profiles of top players, including revenue, profit margins, product lines, and company milestones.

Chapters 5 & 6: Break down revenue performance across regions and countries, offering a precise view of market sizes, opportunities, and development prospects worldwide.

Chapter 7: Examines segmentation by type, revealing the size and potential of each category guiding businesses toward untapped, high-impact areas.

Chapter 8: Focuses on applications, evaluating how different downstream markets are growing and identifying promising sectors for expansion.

Chapter 9: Maps the entire industry supply chain, detailing both upstream and downstream activities for a holistic understanding.

Chapter 10: Concludes with key findings and the most critical takeaways giving stakeholders a clear direction for future strategies.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/infectious-diseases-treatment-market?kb

FAQ's

Q1: How fast is the Infectious Diseases Treatment Market growing?

A: The market is set to grow at a CAGR of 3.9% between 2025 and 2032, showing steady global expansion.

Q2: Which Regions lead the Infectious Diseases Treatment Market?

A: North America leads infectious disease treatment market 43.17%; Asia-Pacific fastest, CAGR 5.2% in (2024)

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.